| Sign In to gain access to subscriptions and/or personal tools. |
Evaluation of Fluorescence- and Mass Spectrometry—Based CYP Inhibition Assays for Use in Drug DiscoveryADME Profiling Cambridge, Metabolism and Pharmacokinetics, Global Discovery Chemistry, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, leslie.bell{at}novartis.com
ADME Profiling Cambridge, Metabolism and Pharmacokinetics, Global Discovery Chemistry, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts
ADME Profiling Cambridge, Metabolism and Pharmacokinetics, Global Discovery Chemistry, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts
ADME Profiling Cambridge, Metabolism and Pharmacokinetics, Global Discovery Chemistry, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts
Central Technologies-US, Discovery Technologies, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts
Central Technologies-US, Discovery Technologies, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts
ADME Profiling Basel, Metabolism and Pharmacokinetics, Global Discovery Chemistry, Basel, Switzerland
ADME Profiling Basel, Metabolism and Pharmacokinetics, Global Discovery Chemistry, Basel, Switzerland
Lead Finding Platform-US, Discovery Technologies, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts
Lead Finding Platform-US, Discovery Technologies, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts
The potential for metabolism-related drug-drug interactions by new chemical entities is assessed by monitoring the impact of these compounds on cytochrome P450 (CYP) activity using well-characterized CYP substrates. The conventional gold standard approach for in vitro evaluation of CYP inhibitory potential uses pooled human liver microsomes (HLM) in conjunction with prototypical drug substrates, often quantified by LC-MS/MS. However, fluorescent CYP inhibition assays, which use recombinantly expressed CYPs and fluorogenic probe substrates, have been employed in early drug discovery to provide low-cost, high-throughput assessment of new chemical entities. Despite its greatly enhanced throughput, this approach has been met with mixed success in predicting the data obtained with the conventional gold standard approach (HLM+LC-MS). The authors find that the predictivity of fluorogenic assays for the major CYP isoforms 3A4 and 2D6 may depend on the quality of the test compounds. Although the structurally more optimized marketed drugs yielded acceptable correlations between the fluorogenic and HLM+LC-MS/MS assays for CYPs 3A4, 2D6, and 2C9 (r2 = 0.5-0.7; p < 0.005), preoptimization, early discovery compounds yielded poorer correlations (r2
Key Words: CYP inhibition • fluorogenic substrates • drug safety screening • human liver microsomes • drug-drug interactions
This version was published on June
1, 2008 Journal of Biomolecular Screening, Vol. 13, No. 5,
343-353 (2008) |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
|
Sign In to gain access to subscriptions and/or personal tools.
0.2) for 2 of these major isoforms, CYPs 3A4 and 2D6. Potential reasons for the observed differences are discussed. (Journal of Biomolecular Screening 2008;343-353)